CLSN will bounce bacck to $9 before release Phase III results
Celsion Corporation (CLSN)
Celsion is an oncology drug development corporation focused on the development and commercialization of treatments for those suffering from different forms of cancer. The company is currently conducting its Phase III clinical trial for ThermoDox. This treatment will have the potential to treat primary liver cancer.
The future of the firm will be completely dependent upon its Phase III results which will be released by the end of January 2013. The CEO has stated this drug has the potential to generate yearly revenues of $1 billion. If successful, it will become the primary treatment for primary liver cancer around the world. With the current market capitalization sitting at just under $328 million, you can do the math and realize how much investors stand to gain.
Celsion has been able to improve its financial status during the last quarter. For the quarter ended September 30, 2012, the company reported a net loss of $6.0 million compared to a net loss for the same period a year ago of $6.4 million. The company was also able to burn less cash during the quarter ended September 30. It spent $16.2 million compared to the same period a year ago where it used $18.3 million. In addition to the improving numbers, the company has also promised not to issue any additional shares until after the ThermoDox Phase III data release in January 2013.
With its trial results due any time now, investors need to be concerned with the risk of bad data. If this occurs, the stock will likely drop below $1 and longs will lose almost their entire investment. But based on what I've seen thus far, I don't expect this to occur.
A side note regarding Celsion: Celsion saw heavy volume today along with violent price swings. The stock traded as high as $9.43 and as low as $6.17. This was due to a circuit breaker issue which caused a dramatic sell-off. The stock has since bounced back, although not to the level it has been in recent days. I would expect the stock to bounce back up to $9 before the Phase III trial results are released.
Yes, it is a great BUY at this level
Prolapse literally means "to fall out of place‚" from the Latin prolabi meaning "to fall out."
In medicine, prolapse is a condition where organs, such as the uterus, fall down or slip out of place. It is used for organs protruding through the vagina or the rectum or for the misalignment of the valves of the heart. A spinal disc herniation is also sometimes called "disc prolapse."
Relating to the uterus, prolapse condition results in an inferior extension of the organ into the vagina, causing weakened muscles.
Yup. This post has just as much to do with NOK as yours.
Strong Buy on Nokia
Run screaming from the building from any pharm being pumped on message boards.
NOK is a buy and I am holding 590K shares.
CLSN is a great stock to buy and HOLD. Buy as much as you can afford. Upside potential is more likely.
I kid you not. Chinese scientist insider knew what is going on. The Chinese when they bite on the deal. They knew at least something that will make back their investment.